NCT00755586

Brief Summary

The purpose of this study is to assess muscle improvement after stem cell injection in the biceps muscle of patients with a brachial plexus injury.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
18

participants targeted

Target at P25-P50 for phase_1

Timeline
Completed

Started Jan 2009

Typical duration for phase_1

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 18, 2008

Completed
1 day until next milestone

First Posted

Study publicly available on registry

September 19, 2008

Completed
3 months until next milestone

Study Start

First participant enrolled

January 1, 2009

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2011

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2011

Completed
Last Updated

August 18, 2009

Status Verified

August 1, 2009

Enrollment Period

2 years

First QC Date

September 18, 2008

Last Update Submit

August 17, 2009

Conditions

Keywords

Brachial plexusMuscle denervationStem cell transplantationBone marrow cellsSatellite cellsFibrosis

Outcome Measures

Primary Outcomes (1)

  • To assess muscle improvement, muscle biopsies, quantitative needle EMGs, muscle density analysis, force measurement, range of motion of the elbow joint and quality of life questionnaires will be performed.

    Two years

Secondary Outcomes (1)

  • The secondary research aim of this study is to assess vital signs and to detect signs of hematoma and/or injection at the bone marrow aspiration site, injection site and/or surgical wound.

    Two years

Study Arms (3)

A

EXPERIMENTAL
Procedure: Mononuclear cell injection: 4 * 10e8 cells

B

EXPERIMENTAL
Procedure: Mononuclear cell injection: 8 * 10e8 cells

C

NO INTERVENTION
Procedure: No mononuclear cell injection

Interventions

350 ml bone marrow will be aspirated from the posterior iliac crest under general anesthesia in combination with a muscle tendon transposition surgery. Next, the patients will receive a bone marrow derived mononuclear cell injection of 4 \* 10e8 cells in the m. biceps brachii.

A

650 ml bone marrow will be aspirated from the posterior iliac crest under general anesthesia in combination with a muscle tendon transposition surgery. Next, the patients will receive a bone marrow derived mononuclear cell injection of 8 \* 10e8 cells in the m. biceps brachii.

B

Patients will receive a muscle tendon transposition surgery without bone marrow aspiration or mononuclear cell injection.

C

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • BP patients with paresis of m. biceps brachii (MRC 1,2,3), either after conservative treatment or at least two years after nerve surgery with partial recovery of the elbow flexor
  • Patients capable and willing to give informed consent

You may not qualify if:

  • Function recovery of the elbow flexor (m. biceps brachii) to a MRC motor scale of 0
  • EMG activity: no motor unit potentials
  • Medical history of other central of peripheral neurological disorders
  • Inability to undergo BM harvesting
  • Bleeding diathesis, INR \> 2

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Leiden University Medical Center

Leiden, 2300RC, Netherlands

RECRUITING

MeSH Terms

Conditions

Fibrosis

Condition Hierarchy (Ancestors)

Pathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Rob GHH Nelissen, MD, PhD

    Leiden University Medical Center

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Rob GHH Nelissen, MD, PhD

CONTACT

Study Design

Study Type
interventional
Phase
phase 1
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

September 18, 2008

First Posted

September 19, 2008

Study Start

January 1, 2009

Primary Completion

January 1, 2011

Study Completion

January 1, 2011

Last Updated

August 18, 2009

Record last verified: 2009-08

Locations